Core Viewpoint - The CESHKB index has shown significant growth, with a year-to-date increase of 123.13%, indicating a strong performance in the biotechnology sector listed in Hong Kong [1][2]. Group 1: Index Performance - The CESHKB index opened high but experienced a decline of 1.85%, closing at 9813.36 points with a trading volume of 19.304 billion [1]. - Over the past month, the CESHKB index has risen by 12.30%, and over the last three months, it has increased by 73.10% [1]. Group 2: Index Composition - The CESHKB index is compiled by China Securities Index Co., Ltd. under the commission of China Securities Trading Service Co., Ltd., reflecting the overall performance of biotechnology companies listed in Hong Kong [1]. - The top ten holdings in the CESHKB index include: - CanSino Biologics (14.32%) - Innovent Biologics (9.54%) - BeiGene (8.5%) - 3SBio (8.48%) - WuXi Biologics (8.32%) - WuXi AppTec (6.53%) - Kintor Pharmaceutical (5.21%) - Zai Lab (4.35%) - Ascletis Pharma (4.17%) - Kingstar Biotech (3.84%) [1]. Group 3: Market and Industry Overview - The CESHKB index is entirely composed of companies listed on the Hong Kong Stock Exchange, with a 100% representation from the healthcare sector [2].

Group 1 - The core index, the CESHKB, increased by 3.44% to 9134.3 points with a trading volume of 16.624 billion [1] - The CESHKB has seen significant growth, rising 21.08% in the past month, 48.89% in the last three months, and 97.07% year-to-date [1] - The index is compiled by China Securities Index Co., Ltd. under the commission of China Securities Trading Service Co., Ltd., reflecting the overall performance of biotechnology companies listed in Hong Kong [1] Group 2 - The top ten weighted stocks in the CESHKB include: Kangfang Biotech (13.95%), Innovent Biologics (9.39%), WuXi Biologics (9.1%), 3SBio (8.92%), BeiGene (8.74%), WuXi AppTec (5.72%), Zai Lab (5.05%), Kelun-Biotech (4.83%), Genscript Biotech (4.28%), and Nuo Cheng Jian Hua-B (4.11%) [1] - The CESHKB is exclusively composed of stocks from the Hong Kong Stock Exchange, with 100% representation [2] - The index's holdings are entirely within the healthcare sector, specifically focusing on pharmaceuticals and biotechnology [2]

Core Insights - The CESHKB index has shown significant growth, with a 23.67% increase over the past month, 51.27% over the last three months, and a remarkable 96.00% year-to-date [1][2] Group 1: Index Performance - The CESHKB index opened high and closed at 8782.49 points with a trading volume of 16.229 billion [1] - The index is designed to reflect the overall performance of biotechnology companies listed in Hong Kong, with a base date of December 12, 2014, set at 2000.0 points [1] Group 2: Index Composition - The top ten holdings of the CESHKB index include: - CanSino Biologics (13.88%) - Innovent Biologics (9.7%) - BeiGene (8.94%) - WuXi Biologics (8.87%) - 3SBio (8.79%) - WuXi AppTec (5.65%) - Zai Lab (5.18%) - Kelun-Biotech (4.9%) - Legend Biotech-B (4.39%) - Genscript Biotech (4.14%) [1] Group 3: Market and Industry Overview - The CESHKB index is fully comprised of companies listed on the Hong Kong Stock Exchange, with 100% of its holdings in the healthcare sector [2]

Group 1 - The core viewpoint of the article highlights the significant performance of the CESHKB index, which has seen substantial increases over various time frames, indicating a strong market trend in the biotechnology sector in Hong Kong [1][2]. - The CESHKB index rose by 3.66% to 7559.76 points, with a trading volume of 12.113 billion [1]. - Over the past month, the CESHKB index has increased by 15.96%, by 28.51% over the last three months, and has risen 62.76% year-to-date [1]. Group 2 - The CESHKB index is compiled by China Securities Index Co., Ltd. and aims to reflect the overall performance of biotechnology companies listed in Hong Kong [1]. - The index is based on a reference date of December 12, 2014, with a base point of 2000.0 [1]. - The top ten holdings of the CESHKB index include companies such as CanSino Biologics (10.79%), Innovent Biologics (10.03%), and BeiGene (9.56%) [1]. Group 3 - The market composition of the CESHKB index is entirely based on the Hong Kong Stock Exchange [2]. - In terms of industry distribution, biopharmaceuticals account for 56.98%, pharmaceutical and biotechnology services for 24.70%, chemical drugs for 16.03%, and medical devices for 2.29% [2].